CDEK
← All organizations

Bioverativ Therapeutics Inc.

For profitContributed to NME

Also known as: Bioverativ Therapeutics Inc. | Bioverativ Therapeutics, Inc. | BIOVERATIV THERAPEUTICS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jan 1, 2017

First marketed drug

Jan 1, 2017

Last known activity

Mar 29, 2018

Acquired by Sanofi-Aventis on Jan 22, 2018

Timeline

2010s

  1. Mar 28, 2014

    coagulation factor ix (Recombinant), Fc-fusion protein— NDA Organization

  2. Jun 6, 2014

    antihemophilic factor viii (Recombinant), Fc-fusion protein— NDA Secondary Org

  3. Jan 1, 2017

    Bioverativ Therapeutics Inc.— Founded

  4. May 23, 2017

    True North Therapeutics— Acquired

  5. Jan 22, 2018

    Sanofi-Aventis— Acquired By

2020s

  1. Feb 4, 2022

    sutimlimab— Marketing Organization

Drugs by trial phase (10 distinct, 19 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 2 (2 own, 0 via acquisition)

Phase 1 (0 own, 1 via acquisition)

Indications

Studied for

Marketed drugs (3)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (23)

Details

Founded
Waltham, MA, US Jan 1, 2017
Last known activity
Mar 29, 2018

Designations held

  • Orphan drug